Latest & greatest articles for venlafaxine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on venlafaxine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on venlafaxine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for venlafaxine

41. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK

A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK Wade A G, Toumi (...) daily) and venlafaxine-XR (VEN; 75 - 150 mg daily). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of adult patients (older than 18 years) with MDD. MDD was defined as baseline scores in the range of 18 to 40 inclusive on the Montgomery-Asberg Depression Rating Scale (MADRS). Setting The setting was primary care. The economic study was carried out in the UK. Dates to which data relate

NHS Economic Evaluation Database.2005

42. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder

Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder van Baardewijk M, Vis P M, Einarson T R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) dose of 40 to 120 mg duloxetine or 75 to 225 mg venlafaxine-XR. The exclusion criteria included diagnosis of any psychiatric condition other than MDD, any major co-morbidity, and use of other psychotropic drugs during the study (with the exception of occasional hypnotic agents or tranquilisers). A further exclusion criterion was evidence of therapy resistance (prior treatment with one of the study drugs, or failure of more than one antidepressant treatment). Setting The hypothetical setting

NHS Economic Evaluation Database.2005

43. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder

Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major (...) depressive disorder Trivedi M H, Wan G J, Mallick R, Chen J L, Casciano R, Geissler E C, Panish J M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Venlafaxine extended release (VXR) was compared

NHS Economic Evaluation Database.2004

44. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis Smith D, Dempster C, Glanville J, Freemantle N, Anderson I Authors' objectives (...) To investigate the relative efficacy and tolerability of venlafaxine compared with other antidepressants. Searching Relevant trials were identified from the authors' existing database (see Other Publications of Related interest no.1). In addition, the following databases were searched: MEDLINE, EMBASE, BIOSIS Previews, PsycLIT, the National Research Register, HealthSTAR, SIGLE, the Cochrane Controlled Trials Register and the Current Controlled Trials Register. The keywords were 'venlafaxine', 'efexor

DARE.2002

45. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.

Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. 11145492 2000 12 28 2001 01 18 2015 11 19 0140-6736 356 9247 2000 Dec 16 Lancet (London, England) Lancet Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. 2059-63 Hot flashes can be troublesome, especially when hormonal therapy is contraindicated. Preliminary data have suggested that newer antidepressants, such as venlafaxine, can diminish (...) hot flashes. We undertook a double-blind, placebo-controlled, randomised trial to assess the efficacy of venlafaxine in women with a history of breast cancer or reluctance to take hormonal treatment because of fear of breast cancer. Participants were assigned placebo (n=56) or venlafaxine 37.5 mg daily (n=56), 75 mg daily (n=55), or 150 mg daily (n=54). After a baseline assessment week, patients took the study medication for 4 weeks. All venlafaxine treatment started at 37.5 mg daily and gradually

Lancet2000

46. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. 10865302 2000 07 11 2000 07 11 2016 10 17 0098-7484 283 23 2000 Jun 21 JAMA JAMA Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. 3082-8 Generalized anxiety disorder (GAD) is a chronic disorder that is associated with debilitating psychic (...) and somatic symptoms. Venlafaxine extended-release (XR) capsules have been shown to be effective in short-term treatment of patients with GAD without major depressive disorder (MDD), but long-term data are needed to establish whether this agent confers persistent benefits. To compare the 6-month efficacy and safety of a flexible dosage of venlafaxine XR in outpatients with GAD without associated MDD. Six-month, randomized, double-blind, placebo-controlled, parallel-group trial conducted May 1996

JAMA2000

47. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder

Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder Einarson T R, Addis A, Iskedjian M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Venlafaxine in the treatment of acute depressive disorders. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patient characteristics are published elsewhere, with a meta-analysis of effectiveness data. Setting Inpatient and outpatient settings were included. The economic analysis was carried out in Ontario, Canada. Dates to which data

NHS Economic Evaluation Database.1997

48. Venlafaxine XR

Venlafaxine XR Oregon Health & Science University OHSU Digital Commons FDA Drug Approval Documents October 1997 V enlafaxine XR United States. Food and Drug Administration. Follow this and additional works at: http://digitalcommons.ohsu.edu/fdadrug This Article is brought to you for free and open access by OHSU Digital Commons. It has been accepted for inclusion in FDA Drug Approval Documents by an authorized administrator of OHSU Digital Commons. For more information, please contact champieu (...) @ohsu.edu. Recommended Citation United States. Food and Drug Administration., "Venlafaxine XR" (1997). FDA Drug Approval Documents. 25. http://digitalcommons.ohsu.edu/fdadrug/251.2.1 Coatzolle4 Sta4i.s 1.2.1 .. 1 8tU4y 208 Igye,tiqltgr,ILpgltipn, principal investigators and study site. are identified in Appendix 7.2.1.1. As discussed in section 5.4, efficacy data from site #13 was couidGrad of questionable rtlillability" . Thus, the sponsor was requested to reanalyze the efficacy results of this stud.y

FDA Drug Approval Documents (via OHSU)1997

49. Venlafaxine

Venlafaxine Oregon Health & Science University OHSU Digital Commons FDA Drug Approval Documents December 1993 V enlafaxine United States. Food and Drug Administration. Follow this and additional works at: http://digitalcommons.ohsu.edu/fdadrug This Article is brought to you for free and open access by OHSU Digital Commons. It has been accepted for inclusion in FDA Drug Approval Documents by an authorized administrator of OHSU Digital Commons. For more information, please contact champieu (...) @ohsu.edu. Recommended Citation United States. Food and Drug Administration., "Venlafaxine" (1993). FDA Drug Approval Documents. 24. http://digitalcommons.ohsu.edu/fdadrug/24.. .. . , . DBLB .1 .. . . . .. .., ,. .. CIMGUI _ usa ••• rr;leAtr saus G ItnIIIf-.,. .. , NfIIll1'S._ .., .. .. . /' .. , IIIMIU 1'0lil1 • '1 . .~ . " llne ... ari 91 629.1) TI (30.4) ,., m.4) 75 (29.') ~ . . " lit t...: 91 ·3.1 77 -3.7 • 79 "4 •• 75 "'.9 .- .066 . .012 " e; • lit 2 ". -4.7 77 ·7.3 79 -7.0 .75 5 '.154 , .069 .001

FDA Drug Approval Documents (via OHSU)1993